North America Vaccines Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
to 2027 - Regional Analysis and Forecasts by Technology (Recombinant Vaccines, Conjugate Vaccines, Live Attenuated Vaccines, Inactivated and Subunit Vaccines, and Toxoid Vaccines); Disease Indication (DTP (Diphtheria Tetanus toxoids and Pertussis), Influenza, Hepatitis, Respiratory Syncytial Virus (RSV), and Other Diseases); Route of Administration (Oral, Injectable, and Other Routes of Administration); Patient Type (Pediatric Patients, and Adult Patients), and Country

No. of Pages: 142    |    Report Code: TIPRE00003512    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
North America Vaccines Market

PART 1. iNTRODUCTION

1.1      Scope of the Study

1.2      The Insight Partners Research Report Guidance

PART 2. North America Vaccines Market -  Key takeaways

PART 3. North America Vaccines market - market landscape

3.1      overview

3.2      market segmentation

3.2.1      North America Vaccines Market - By Technology

3.2.2      North America Market - By Disease Indication

3.2.3      North America Vaccines Market - By Route of Administration

3.2.4      North America Vaccines Market - By Patient Type

3.2.5      North America Vaccines Market - By Country

3.3      PEST Analysis

PART 4. North America VAccines market- Key Market Dynamics

4.1      Key Market Drivers

4.1.1      Compulsion or Mandate Vaccination

4.1.2      Dropping Vaccination Rates

4.2      Key Market Restraints

4.2.1      Low Awareness About the Benefits of Vaccines

4.3      Key Market Opportunities

4.3.1      Rising Numbers of Diseases

4.4      future Trends

4.4.1      Advances in Vaccine Technology

4.5      Impact analysis

PART 5. VAccines market - North America Analysis

5.1      North America Vaccines market Revenue Forecasts and Analysis

5.2      Market positioning

5.3      PERFORMANCE OF KEY PLAYERS

PART 6. North America vaccines market Analysis - By TEchnology

6.1      Overview

6.2      NORTH AMERICA vaccines MARKET, BY Type, 2018 & 2027 (%)

6.3      North America Vaccines market Revenue And Forecasts to 2027, By echnology (US$ Mn)

6.4      Norh America Recombinant Vaccines Market

6.4.1      Overview

6.4.2      North America Recombinant Vaccines Market Revenue and Forecast to 2027 (US$ Mn)

6.5      North America Conjugate Vaccines Market

6.5.1      Overview

6.5.2      North America Conjugate Vaccines Market Revenue and Forecast to 2027 (US$ Mn)

6.6      North America Live Attenuated Vaccines Market

6.6.1      Overview

6.6.2      North America Live Attenuated Vaccines Market Revenue and Forecast to 2027 (US$ Mn)

6.7      North America Inactivated Vaccines Market

6.7.1      Overview

6.7.2      North America Inactivated Vaccines Market Revenue and Forecast to 2027 (US$ Mn)

6.8      North America toxoid Vaccines Market

6.8.1      Overview

6.8.2      North America Toxoid Vaccines Market Revenue and Forecast to 2027 (US$ Mn)

PART 7. North America Vaccines market Analysis - By Disease Indication

7.1      Overview

7.2      NORTH AMERICA vaccines MARKET, BY disease indication, 2018 & 2027 (%)

7.3      North America Vaccines market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)

7.4      North America DTP (diphtheria, tetanus, and pertussis) Market

7.4.1      Overview

7.4.2      North America DTP (Diphtheria, Tetanus, And Pertussis) Market Revenue and Forecast to 2027 (US$ Mn)

7.5      North AMerica Influenza Market

7.5.1      Overview

7.5.2      North America Influenza Market Revenue and Forecast to 2027 (US$ Mn)

7.6      North America Hepatitis Market

7.6.1      Overview

7.6.2      North America Hepatitis Market Revenue and Forecast to 2027 (US$ Mn)

7.7      North America Other Diseases Market

7.7.1      Overview

7.7.2      North America Other Diseases Market Revenue and Forecast to 2027 (US$ Mn)

PART 8. North America Vaccines market Analysis - By Route of administration

8.1      Overview

8.2      NORTH AMERICA Vaccines MARKET, BY route of administration, 2018 & 2027 (%)

8.3      North America Vaccines market Revenue And Forecasts to 2027, By route of administration (US$ Mn)

8.4      North America Oral Market

8.4.1      Overview

8.4.2      North America Oral Market Revenue and Forecast to 2027 (US$ Mn)

8.5      North AMerica Injectable Market

8.5.1      Overview

8.5.2      North America Injectable Market Revenue and Forecast to 2027 (US$ Mn)

8.6      North America Other Routes of Administration Market

8.6.1      Overview

8.6.2      North America Other Routes of Administration Market Revenue and Forecast to 2027 (US$ Mn)

PART 9. North America Vaccines market Analysis - By Patient type

9.1      Overview

9.2      NORTH AMERICA Vaccines MARKET, BY patient type, 2018 & 2027 (%)

9.3      North America Vaccines market Revenue And Forecasts to 2027, By patient type (US$ Mn)

9.4      North America pediatric Market

9.4.1      Overview

9.4.2      North America Pediatric Market Revenue and Forecast to 2027 (US$ Mn)

9.5      North America adults Market

9.5.1      Overview

9.5.2      North America Adults Market Revenue and Forecast to 2027 (US$ Mn)

PART 10. North America Vaccines market Revenue and Forecasts to 2027

10.1    Overview

10.1.1     North America Vaccines Market Revenue And Forecasts to 2027 (US$ Mn)

10.1.2     North America Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)

10.1.3     North America Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)

10.1.4     North America Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

10.1.5     North America Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)

10.1.6     North America Vaccines Market Revenue And Forecasts to 2027, By Country (%)

10.1.7     US Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

10.1.8     US Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

10.1.8.1   US Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)

10.1.8.2   US Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)

10.1.8.3   US Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

10.1.8.4   US Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)

10.1.9     Canada Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

10.1.10   Canada Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

                         10.1.10.1 Canada Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)

                         10.1.10.2 Canada Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)

                         10.1.10.3 Canada Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

10.1.10.4.. Canada Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)

10.1.11   Mexico Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

10.1.12   Mexico Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

                         10.1.12.1 Mexico Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)

                         10.1.12.2 Mexico Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)

                         10.1.12.3 Mexico Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

                         10.1.12.4 Mexico Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)

PART 11. Vaccines Market -Industry Landscape

11.1    Overview

11.2    Comparative Company Analysis

11.3    Growth Strategies done by the companies in the Market, (%)

11.4    Organic Developments

11.4.1     Overview

11.5    Inorganic developments

11.5.1     Overview

PART 12. Vaccines Market-Key company profiles

12.1    PFIZER INC.

12.1.1     Key Facts

12.1.2     Business Description

12.1.3     Financial Overview

12.1.4     Product Portfolio

12.1.5     SWOT Analysis

12.1.6     Key Developments

12.2    GlaxoSmithKline plc.

12.2.1     Key Facts

12.2.2     Business Description

12.2.3     Financial Overview

12.2.4     Product Portfolio

12.2.5     SWOT Analysis

12.2.6     Key Developments

12.3    Merck & Co., Inc.

12.3.1     Key Facts

12.3.2     Business Description

12.3.3     Financial Overview

12.3.4     Product Portfolio

12.3.5     SWOT Analysis

12.3.6     Key Developments

12.4    Sanofi

12.4.1     Key Facts

12.4.2     Business Description

12.4.3     Financial Information

12.4.4     Product Portfolio

12.4.5     SWOT Analysis

12.4.6     Key Developments

12.5    Johnson & Johnson Services, Inc.

12.5.1     Key Facts

12.5.2     Business Description

12.5.3     Financial Overview

12.5.4     Product Portfolio

12.5.5     SWOT Analysis

12.5.6     Key Developments

12.6    Panacea Biotec Limited

12.6.1     Key Facts

12.6.2     Business Description

12.6.3     Financial Information

12.6.4     Product Portfolio

12.6.5     SWOT Analysis

12.6.6     Key Developments

12.7    Astellas Pharma Inc.

12.7.1     Key Facts

12.7.2     Business Description

12.7.3     Financial Overview

12.7.4     Product Portfolio

12.7.5     Swot Analysis

12.7.6     Key Developments

12.8    NOVAVAX, INC.

12.8.1     Key Facts

12.8.2     Business Description

12.8.3     Financial Information

12.8.4     Product Pipeline

12.8.5     SWOT Analysis

12.8.6     Key Developments

12.9    VBI Vaccines Inc.

12.9.1     Key Facts

12.9.2     Business Description

12.9.3     Financial Information

12.9.4     Product Portfolio

12.9.5     SWOT Analysis

12.9.6     Key Developments

12.10   BAVARIAN NORDIC

12.10.1   Key Facts

12.10.2   Business Description

12.10.3   Financial Information

12.10.4   Product Pipeline

12.10.5   SWOT Analysis

12.10.6   Key Developments

PART 13. Appendix

13.1    About The Insight Partners

13.2    Glossary of Terms

13.3    Methodology

13.3.1     Coverage

13.3.2     Secondary Research

13.3.3     Primary Research

 

LIST OF TABLES

TABLE 1.           North America Vaccines market Revenue And Forecasts to 2027, By Technology (US$ Mn)

TABLE 2.           North America Vaccines market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)

TABLE 3.           North America vaccines market Revenue And Forecasts to 2027, By route of administration (US$ Mn)

TABLE 4.           North America vaccines market Revenue And Forecasts to 2027, By patient type (US$ Mn)

TABLE 5.           North America Vaccines market Revenue And Forecasts to 2027, By Technology (US$ Mn)

TABLE 6.           North America Vaccines market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)

TABLE 7.           North America Vaccines market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

TABLE 8.           North America Vaccines market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)

TABLE 9.           US Vaccines market Revenue And Forecasts to 2027, By Technology (US$ Mn)

TABLE 10.          US Vaccines market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)

TABLE 11.          US Vaccines market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

TABLE 12.          US Vaccines market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)

TABLE 13.          CANADA Vaccines market Revenue And Forecasts to 2027, By Technology (US$ Mn)

TABLE 14.          CANADA Vaccines market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)

TABLE 15.          CANADA Vaccines market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

TABLE 16.          CANADA Vaccines market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)

TABLE 17.          MEXICO Vaccines market Revenue And Forecasts to 2027, By Technology (US$ Mn)

TABLE 18.          MEXICO Vaccines market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)

TABLE 19.          MEXICO Vaccines market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

TABLE 20.          MEXICO Vaccines market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)

TABLE 21.          Organic Developments Done By Companies

TABLE 22.          Inorganic developments done by Companies

TABLE 23.          Glossary of Terms, Vaccines market

 

LIST OF TABLES

FIGURE 1.          US Vaccines market, Revenue (US$ Mn), By COuntry 2018 & 2027

FIGURE 2.          north America Vaccines Market By Type, Market Share (%), 2018

FIGURE 3.          north America vaccines Market By Disease indication, Market Share (%), 2018

FIGURE 4.          North America Vaccines Market By route of Administration, Market Share (%), 2018

FIGURE 5.          North America Vaccines Market By Patient Type, Market Share (%), 2018

FIGURE 6.          Vaccines market Segmentation

FIGURE 7.          North America PEST Analysis

FIGURE 8.          Vaccines market impact analysis of drivers & Restraints

FIGURE 9.          North America Vaccines market - Revenue Forecasts and Analysis - 2018- 2027

FIGURE 10.        North America vaccines market, By Technology, 2018 & 2027 (%)

FIGURE 11.        North America recombinant vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

FIGURE 12.        North America conjugate vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

FIGURE 13.        North America live attenuated vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

FIGURE 14.        North America inactivated vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

FIGURE 15.        North America toxoid vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

FIGURE 16.        North America vaccines market By disease indication, 2017 & 2025 (%)

FIGURE 17.        North America DTP (diphtheria, tetanus, and pertussis) Market Revenue and Forecasts to 2027 (US$ Mn)

FIGURE 18.        North America influenza Market Revenue and Forecasts to 2027 (US$ Mn)

FIGURE 19.        North America hepatitis Market Revenue and Forecasts to 2027 (US$ Mn)

FIGURE 20.        North America Other Diseases Market Revenue and Forecasts to 2027 (US$ Mn)

FIGURE 21.        North America vaccines market By route of administration, 2018 & 2027 (%)

FIGURE 22.        North America oral Market Revenue and Forecasts to 2027 (US$ Mn)

FIGURE 23.        North America injectable Market Revenue and Forecasts to 2027 (US$ Mn)

FIGURE 24.        North America other routes of administration Market Revenue and Forecasts to 2027 (US$ Mn)

FIGURE 25.        North America vaccines market By patient type, 2018 & 2027 (%)

FIGURE 26.        North America pediatric Market Revenue and Forecasts to 2027 (US$ Mn)

FIGURE 27.        North America adults Market Revenue and Forecasts to 2027 (US$ Mn)

FIGURE 28.        North America Vaccines market revenue Overview, by Country (2017) (us $ mn)

FIGURE 29.        North America Market Revenue and Forecasts to 2027 (US$ Mn)

FIGURE 30.        North America Vaccines market Revenue And Forecasts to 2027, By Country (%)

FIGURE 31.        US Vaccines market Revenue and Forecasts to 2027 (US$ Mn)

FIGURE 32.        Canada Vaccines market Revenue and Forecasts to 2027 (US$ Mn)

FIGURE 33.        Mexico Vaccines market Revenue and Forecasts to 2027 (US$ Mn)

FIGURE 34.        Comparative Company Analysis

FIGURE 35.        Growth Strategies done by the companies in the Market, (%)

 

 

The List of Companies - North America Vaccines Market

The List of Companies - North America Vaccines Market

  1. PFIZER INC
  2. GlaxoSmithKline plc.
  3. Merck & Co., Inc.
  4. Sanofi
  5. Johnson & Johnson Services, Inc
  6. Panacea Biotec Limited
  7. Astellas Pharma Inc.
  8. NOVAVAX, INC.
  9. VBI Vaccines Inc
  10. Bavarian Nordic.